Lilly Barrettini has been approved to treat the new crown counting Jak inhibitors on the market and in the research pipeline

Yesterday, the FDA approved an emergency use of a new coronary pneumonia treatment drug (emergency use authorization, EUA) - Lilly JAK inhibitor Baricitinib in the treatment of oxygen-absorbing or breathable hospitalization of new crown patients.
makes the potential of Jak inhibitors shine even more brightly.
November 3rd, the clinical head-to-head of the phase III clinical head-to-head of Therent's $2 billion-a-year sales of selective phosphate 4 (PDE4) inhibitor Otezla was defeated by the selective tyk2 inhibitor Deucracatinib.
October 15th, the New England Journal of Medicine (NEJM) AbbVie Jak1 selective inhibitor Upadacitinib showed better results in a Phase III clinical trial of head-to-head refrectable rheumatoid arthritis III with a $2.98 billion annual sales of Abatacept.
series of results to make JAK inhibitors even hotter.
jak inhibitors are listed and clinically counted in the research pipeline below.
1.Jak inhibitors have six new molecular entities on the market.
three of the products were approved for listing by the FDA, with Incyte and Novarchi's Rusotini later toping sales.
11 products entering phase III clinical phase.
Pfizer and CTI BioPharma's Pacritinib have filed a new drug listing application (NDA) with the FDA.
develops Rusotini emulsions with Incyte, and Hengrui Selective Jak1 inhibitors are the fastest growing in Chinese pharmaceutical companies.
highly selective Jak inhibitors make up the majority of III clinical Jak inhibitors, TD-1473 relies on its unique intestinal targeting characteristics to have a unique competitive advantage, phase I clinical completion was introduced by Johnson and Johnson $1 billion.
3. Enter phase II clinical phase 24 products.
Pfizer at the same time to develop brepocitinib tablets and emulsions, The Chinese pharmaceutical company Zeyi Pharmaceutical two products into Phase II clinical, Hengrui, Reding have a phase II clinical.
4. There are 18 products entering the clinical phase I.
Chinese pharmaceutical companies, Fosun Pharma and Zhengda Tianqing chose to develop highly selective Jak inhibitors, while Colum Biologicals and Zhuhai Federation developed pan-Jak inhibitors.
phase I clinical phase is no shortage of multinational giants, such as Novaral, Roche gene Tektronick and so on.
, Chong Kun Dang Pharma micro-innovated Tofatini and the product entered phase I clinical phase.
Throughout the market and in the pipeline, pan-Jak inhibitors and highly selective inhibitors have their own swings, many manufacturers choose selective inhibition of Jak1, Jak2, Jak3 or Jak2 at the same time targeting other lysine kinases, such as Tec, Flt3, Kit, etc., their respective development of adaptive disorders are also different.
Although the earliest listed JAK inhibitor tofatinib has been in the market for nearly ten years, but JAK inhibitors are very large, adaptive, from RA to Cancer, later in the efficacy and safety of continuous breakthroughs, it is expected that the development of Jak inhibitors will remain hot for some time to come.
。